Search results
Huntington disease (HD) is a rare, inherited, neurodegenerative disorder characterized by progressive motor symptoms including involuntary choreatic movements as well as cognitive, behavioral, and psychiatric changes. 1,2 The disease is caused by an increase in the number of CAG repeats in the DNA sequence of exon 1 of the HTT gene. 3 The overall prevalence of HD is increasing, 4 and the ...
Huntington’s disease (HD) is an inherited neurodegenerative disease characterised by neuropsychiatric symptoms, a movement disorder (most commonly choreiform) and progressive cognitive impairment.
Aug 17, 2017 · Huntington's disease is caused by an autosomal dominantly inherited CAG trinucleotide repeat expansion in the huntingtin (HTT) gene on chromosome 4. This results in the production of a mutant huntingtin (mHTT) protein with an abnormally long polyglutamine repeat 3 .
- Peter McColgan, Sarah J Tabrizi
- 2018
May 27, 2020 · There is currently no cure for Huntington’s, a hereditary neurodegenerative disease, but recent advances in genetic therapies hold great promise. Researchers would ultimately like to treat people before the genetic mutation has caused any functional impairment.
Oct 23, 1998 · Huntington disease (HD) is a progressive disorder of motor, cognitive, and psychiatric disturbances. The mean age of onset is 35 to 44 years, and the median survival time is 15 to 18 years after onset.
- 2020/06/11
Jun 11, 2024 · Huntington’s disease (HD) is a monogenic autosomal-dominant disorder caused by a pathological expansion of trinucleotide repeats (CAG) on exon 1 of the huntingtin (HTT) gene [1]. The estimated prevalence ranges from 8.2 to 9 per 100,000 people in Europe and North America [2].
People also ask
Is Huntington disease a psychiatric disorder?
Who should be diagnosed with Huntington disease (HD)?
Can Huntington aggregates predict neuronal death in Huntington's disease?
Is executive dysfunction associated with striatal and insular atrophy in Huntington's disease?
What is the molecular epidemiology of Huntington disease?
Correspondence to: Dr. Mena Farag, Huntington’s Disease Centre, Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, Russell Square House, 10-12 Russell Square, London, WC1B 5EH, UK. E-mail: [email protected]; ORCID: 0000-0002-0679-0117
